

BIOTIME INC
Form 8-K
May 14, 2012
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **May 14, 2012**

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California

1-12830

94-3127919

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer

Identification No.)

1301 Harbor Bay Parkway

Alameda, California 94502

(Address of principal executive offices)

(510) 521-3390

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions identify forward-looking statements.

Section 7 - Regulation FD

Item 7.01 - Regulation FD Disclosure

On May 14, 2012, we announced the publication of a scientific paper demonstrating the effectiveness of *HyStem*[®]-C in the transplantation of heart muscle-derived cells in an animal model of heart disease. The paper, "Functional performance of human cardiosphere-derived cells delivered in an *in situ* polymerizable hyaluronan-gelatin hydrogel," is published online (ahead of print) in the peer-reviewed journal *Biomaterials*. The report demonstrates that the survival of human heart-derived cells is markedly improved when the cells are formulated in *HyStem*[®]-C, a product being developed by us under the trade name *Renevia*[™] as a cell delivery device.

Additional information about the findings of the study reported in the paper can be found in the press release filed as Exhibit 99.1 and incorporated herein by reference.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
-----------------------	--------------------

99.1	Press release dated May 14, 2012
------	----------------------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: May 14, 2012 By: /s/ Michael
D. West
Chief
Executive
Officer

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated May 14, 2012